Please login to the form below

Not currently logged in
Email:
Password:

Lucid launches rare and specialist disease agency

Vivid MedComms will be headed by Alison Cantle

VividUK-based Lucid Group, has opened Vivid Medcomms, a new agency that will focus on rare diseases and be based in Buckinghamshire, UK.

Vivid will be headed up by managing director Alison Cantle, who was previously a business unit director at Lucid and has over 20 years’ medical communications experience.

She said: “Our business in rare diseases has increased threefold over the last year and making the decision to create a new stand-alone company focused on this area is an obvious choice.”

According to analysts at Evaluate Pharma sales of orphan drugs are set to account for 20% of all prescription drug sales by 2020.

The move mirrors an “industry-wide shift” towards focusing on rare and specialist disease, with revenues from orphan drugs ‘outpacing’ sales of mainstream drugs for the last decade, explained Lucid.

Cantle added: “We have developed a dedicated and talented team of account handlers and medical writers brimming with a specific skills and experience related to developing excellent comms programmes in rare diseases.

“The team are excited by the challenge and looking forward to transforming the lives of both clients and teams in this space.”

Article by
Gemma Jones

13th November 2017

From: Marketing

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...